10-K: Groove Botanicals Inc. 10-K: Focus on Future Tech Licensing

Groove Botanicals Inc. files its annual 10-K report, detailing its transition from past operations to a new strategy focused on identifying and evaluating early-stage intellectual property and applied technologies from Norwegian research institutions for North American commercialization.

Summary

• Groove Botanicals Inc. is an early-stage company transitioning its focus to identifying and evaluating early-stage intellectual property and applied technologies from Norwegian universities and research institutions for potential licensing and commercialization in North America.
• The company has no current products, technologies, or intellectual property rights and is in the process of establishing its new business model.
• Operating expenses for the fiscal year ended March 31, 2026, were $139,917, an increase from $130,834 in the prior year, primarily due to higher consulting expenses.
• The company reported a net loss of $139,917 for the fiscal year ended March 31, 2026, compared to a net loss of $130,834 for the prior year.
• Significant preferred stock dividends, totaling $218,470 for both fiscal years, contributed to the net loss attributable to common shareholders.
• The company has a substantial accumulated deficit of $35,554,968 as of March 31, 2026, raising substantial doubt about its ability to continue as a going concern.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern.
• There are material weaknesses in internal control over financial reporting due to inadequate segregation of duties and lack of an audit committee with a financial expert.
• The company's CEO, Kent Rodriguez, holds significant voting power (51%) through Series A Preferred Stock and is the primary source of related party financing.
• The company is seeking additional capital through equity or debt financing to fund its operations and business objectives.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as having a very negative sentiment due to the significant net losses, growing accumulated deficit, auditor's going concern warning, and material weaknesses in internal controls, despite the stated strategic pivot.

Positives

• The company is actively pursuing a new strategic direction focused on technology licensing and commercialization.
• A clear geographic focus on Norway for identifying research opportunities has been established.
• The company has one full-time employee and utilizes consultants and advisors to manage operations efficiently.
• The company's auditor, GSKCA & Associates, has issued an unqualified opinion on the financial statements for the year ended March 31, 2026, stating they present fairly in all material respects.
• The company has a plan to address going concern issues by focusing on its new business model and raising financing.

Negatives

• The company has generated no revenue since inception and does not expect to generate revenue in the near future.
• The company has a significant accumulated deficit of $35,554,968 as of March 31, 2026.
• The company's auditor has expressed substantial doubt about its ability to continue as a going concern.
• Material weaknesses in internal control over financial reporting exist due to inadequate segregation of duties and lack of an independent audit committee with a financial expert.
• The company has no current products, technologies, or intellectual property rights under contract.
• There is no assurance that suitable technologies will be identified, licensed, developed, or successfully commercialized.
• The company requires substantial additional funds for operations and business objectives, and there is no guarantee of obtaining necessary financing on favorable terms.
• Issuance of additional equity securities will result in dilution for existing stockholders.
• The company's CEO, Kent Rodriguez, holds significant control through Series A Preferred Stock, potentially creating conflicts of interest.
• The company has changed auditors, with Madhava Rao resigning and GSKCA & Associates being engaged.

Risks

• The company is in an early stage of development and has not yet identified or secured any specific technology or intellectual property rights, and there is no assurance that suitable technologies will be identified, licensed, developed, or successfully commercialized.
• The market for identifying, licensing, developing, and commercializing early-stage technologies is highly competitive, and the company may face competition from entities with greater resources.
• The company's ability to continue as a going concern is subject to substantial doubt due to recurring net losses and limited capital raised.
• The company requires substantial additional funds for operations and business objectives, and there is no assurance that financing will be available on favorable terms.
• If additional funds are raised through equity issuance, existing stockholders will experience dilution.
• The company has material weaknesses in internal control over financial reporting, including inadequate segregation of duties and lack of an audit committee with a financial expert.
• The company's reliance on a single executive officer for management and risk assessment presents a concentration of risk.
• The company has limited cybersecurity measures in place due to its current limited exposure, but this could become a material risk as the company grows.

Future Outlook

The company intends to identify and evaluate early-stage intellectual property and applied technologies from Norwegian research institutions for potential licensing, development, or commercialization in North America. Capital needs are anticipated to be between $500,000 and $5,000,000, depending on growth strategies. The company is actively seeking equity or debt financing to fund its operations and business objectives.

Management Comments

• "We intend to identify and evaluate early-stage intellectual property and applied technologies that may originate from, or be developed within, the research ecosystems of Norwegian universities, university hospitals, applied research institutions, and related technology-transfer or innovation organizations, and to assess whether selected technologies may be suitable for licensing, further development, or commercialization in North America."
• "We are in an early stage of development, we have not entered into any licensing agreements or formal arrangements with any of these institutions or any other Norwegian research organization or any university, research institution, or technology transfer organization to date. Nor have we identified or have any specific technology or intellectual property rights under contract, and we do not have proprietary or exclusive access to any technology pipeline."
• "We are in need of additional cash resources to maintain our operations."
• "Our auditors express substantial doubt about our ability to continue as a going concern."
• "We would need to hire additional staff to provide greater segregation of duties. Currently, it is not feasible to hire additional staff to obtain optimal segregation of duties."
• "We will continue to monitor the effectiveness of this action and make any changes that our management deems appropriate."

Industry Context

StockSavvy.ai notes that Groove Botanicals Inc. is pivoting towards a technology scouting and licensing model, a strategy common among early-stage companies seeking to leverage external innovation. The focus on Norwegian research institutions suggests a targeted approach to intellectual property acquisition, aiming to capitalize on specific technological strengths within that region. This strategy is highly dependent on successful identification, negotiation, and commercialization of intellectual property, facing significant competition from established players and venture capital firms.

Comparison to Industry Standards

• The company's current operational model, with minimal staff and reliance on outsourced services, is typical for very early-stage ventures. However, its lack of revenue and significant accumulated deficit are concerning when compared to industry standards for companies at a similar stage of strategic development.
• The company's approach to identifying technology from Norwegian universities is a niche strategy. Benchmarking against similar technology scouting firms would require identifying direct competitors with similar geographic and technological focuses.
• The company's financial performance, characterized by net losses and a negative cash flow from operations, is not aligned with industry standards for companies that have successfully commercialized technologies. The significant preferred stock dividends also place a considerable burden on common shareholders.
• The material weaknesses in internal controls are a significant deviation from industry best practices and regulatory expectations for publicly traded companies, even smaller ones.

Management Changes

Corporate Governance

Related Party Transactions

• Related party payables totaled $747,961 as of March 31, 2026, consisting of funds contributed by management for operations and compensation.
• Kent Rodriguez, the CEO, is the sole holder of Series A Preferred Stock and holds 18.6% of Series B Preferred Shares.
• Accrued dividends on Series A Preferred Stock to Kent Rodriguez were $40,000 for the fiscal year ended March 31, 2026.
• Accrued dividends on Series B Preferred Shares to Kent Rodriguez were $33,195 for the fiscal year ended March 31, 2026.
• The company has a related party payable of $747,961 and $608,833 outstanding as of March 31, 2026, and March 31, 2025, respectively, representing funds contributed by management.
• The company accrues $48,000 annually for wages payable to CEO Kent Rodriguez.
• The Series A Convertible Preferred Stock carries a liquidation preference of $500,000.

Stakeholder Impact

• Shareholders: Potential for significant dilution if equity financing is pursued; current common stock value is very low; substantial accumulated deficit and going concern issues impact investment value.
• Employees: The company has only one full-time employee (CEO) and a part-time administrative assistant, with consultants and advisors used on an as-needed basis.
• Creditors: The company's going concern status and financial condition may impact its ability to meet obligations.
• Management (Kent Rodriguez): Holds significant control through Series A Preferred Stock and is a primary source of financing, creating potential conflicts of interest but also ensuring operational continuity through funding.

Next Steps

• Identify and evaluate early-stage intellectual property and applied technologies from Norwegian research institutions.
• Assess suitability of identified technologies for licensing, further development, or commercialization in North America.
• Secure necessary financing (equity or debt) to fund operations and business objectives.
• Address material weaknesses in internal control over financial reporting.
• Continue to monitor and manage cybersecurity risks as the company grows.

Key Dates

Recommendation

The company is in a highly speculative early stage with a new strategy, but faces significant financial challenges, including a going concern warning and material control weaknesses. While the pivot to technology licensing offers potential, the lack of revenue, substantial deficit, and need for significant capital make it a high-risk investment. A 'hold' recommendation reflects the uncertainty and speculative nature, pending evidence of successful technology acquisition and commercialization, and resolution of financial and control issues.

Keywords

Groove Botanicals Inc., 10-K, Annual Report, Technology Licensing, Intellectual Property, Norway Research, Early-Stage Technology, Commercialization, Going Concern, Net Loss, Operating Expenses, Related Party Transactions, Capital Raise, Internal Controls